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ABSTRACT
Jacob Garrett Thrasher: Targeting Metastatic Breast Cancer with Statin Drugs
(Under the direction of Dr. Yu-Dong Zhou and Dr. Dale George Nagle)
Statin drugs are commonly prescribed to lower cholesterol levels in patients, but
recently statins have been under investigation as a potential anti-cancer drug. Statins are
HMG-CoA reductase inhibitors and subsequently inhibit the mevalonate pathway and
cholesterol synthesis. Since cholesterol trafficking is vital in the growth and metastasis of
cancer, statin drugs are being studied to explore their effects on cancer cells. CoQ10, one
of the products from the mevalonate pathway, also has shown some potential anti-cancer
properties, but its use to combat cancer is controversial. While some studies have shown
that CoQ10 supplements can be synergistic with other cancer treatment methods, the
biochemical mechanisms of CoQ10’s potential anti-cancer properties are poorly
understood. In this experiment, the anti-cancer potentials of lovastatin and CoQ10 were
studied using the breast cancer cell lines BoM-1833 (BoM) derived from MDA-231,
MCF7/BoM, and T47D. The IC50 values for lovastatin were found to be 4.89×10-06 M
(BoM) and 4.06×10-06 M (MCF7/BoM). The IC50 values for CoQ10 were found to be
5.46×10-07 M (BoM) and 8.86×10-07 M (MCF7/BoM). IC50 values for lovastatin and
CoQ10 with the cell line T47D were not found because the drugs did not sufficiently inhibit
the growth of the T47D cells.
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1 Introduction
1.1  The Value of a Biochemical Approach to Cancer Research
Studying cancer and looking for new therapies can be approached from many
different perspectives such as genetic approaches, biological approaches, and biochemical
approaches. Cancers utilize altered metabolic pathways, so studying the biochemistry of
cancers is a great way to understand how and why these altered pathways work and
potentially target these pathways for treatment. One of the most recognized altered
biochemical tumor pathways is known as the Warburg effect.1 This altered pathway affects
the metabolic state of cancer by changing the means of energy production in cancer cells.1
Normal cells produce ATP through oxidative phosphorylation, but the Warburg effect is
where cancer cells predominantly produce their ATP through an increased rate of aerobic
glycolysis.1 Cholesterol metabolism is another pathway that is disrupted in cancer cells and
this altered metabolism supports the uncontrolled cell growth which is a key feature of
cancer. This cholesterol metabolic change causes high concentrations of cholesterol in
mitochondria which in turn may contribute to the Warburg effect while changing the
chemistry of the mitochondrial membrane to prevent mitochondrial apoptosis.2 Better
understanding these compromised pathways open up doors for new drug targets and a
better overall understanding of cancers.

1.2  Metastasis
The most life-threatening attribute of cancer is metastasis, the spread and vigorous
growth of cells from the primary neoplasm to distant organs. The spread of cancer to distal
organs is not a random process, but one that is controlled by the properties of both the
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tumor and the micro-environment of the target organ. The first explanation for this nonrandom pattern of metastasis was published in 1889 by Stephen Paget and is known as the
“seed and soil” hypothesis.3 He stated that the outcomes of metastasis depended on the
properties of the specific tumor cell, the ‘seed,’ and the environment of specific organs, the
‘soil.’3 The ‘seed and soil’ hypothesis has stood strong for over 100 years, and is the
foundation for modern metastatic studies.
Metastasis occurs through a complex multistep process: invasion of cancer cell
through the basement membrane, invasion of the vascular system, survival in
cardiovascular circulation, attachment to blood vessel walls, extravasation to an organ, and
the colonization and growth of a neoplasm.4 Each one of these steps have to be successfully
executed for the cancer to spread to a new organ, and abrogation of any of the steps in this
process can halt the metastasis.4 Advances in understanding the mechanisms behind
metastasis are not advanced as other developments in the cancer field; therefore, there are
many opportunities for new therapies to arise from metastatic studies.
The success of metastasis is dependent on both the properties of the tumor cells and
the properties of the target site. The ability for tumors to be heterogeneous promotes a
cancers ability to metastasize. At the beginning of initial tumor formation, most neoplasms
are already heterogeneous and contain multiple subpopulations of cancerous cells.5 Only a
few cells from the primary tumor need to possess metastatic qualities for a distal neoplasm
to form. Some cells in the primary tumor may contain some metastatic properties, but only
the cells that possess all the necessarily qualities for metastasis will actually metastasize.5,6
Metastases can have unicellular or multicellular origins just like primary neoplasms, and
therefore neoplasms can also be heterogeneous.6
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Primary neoplasm

1

Progressive growth
✔
Vascularization
✔
Invasion
✔
Detachment
Embolization
Survival in Circulation
Arrest
Extravasation
Evasion of host defense

2

3

4

5

✔
✔
✔
✔
✔

✔
✔

✔
✔
✔

✔
✔
✔
✔
✔
✔
✔
✔
✔

✔
✔
✔
✔

Secondary Neoplasm
✔
Table 1.1 Each sequential step of metastasis is likely regulated by mutations and
modifications in the cancer cell. Only cells that have the mutations (symbolized by ✔) for
all the steps will successfully undergo metastasis and form a secondary neoplasm.
Metastasis can be blocked at any step which would prevent the secondary neoplasm from
forming. Not only must the cell have the mutations for the traits above, the cell also must
find the proper metastatic site.5

Figure 1.1. A primary neoplasm going through the sequential metastatic steps to form a
secondary neoplasm.
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1.3 Organotropism
Metastasis is a non-random process contrary to previous belief. Recent studies have
confirmed the process is specific and relies on intricate tumor-stroma interactions.5 The
ability for certain cancers to spread to specific organs is known as organotropism, and each
type of cancer has a specific organotropic pattern. In the 1970s, Fider and co-workers
observed in a metastatic assay that the cancer cells derived from a specific secondary site
have heightened metastatic affinity to the specific organ.6 Tumor gene expression profiling
studies support the organotropism hypothesis by revealing distance gene expression
patterns for organ-specific secondary neoplasms.7,8 Breast cancer is responsible for over
40,000 deaths annually in the United States, most of which are due to metastasis to other
organs.9 Breast cancer usually metastasizes to lung, bone, brain, or liver tissue. Breast
cancer metastasis to the kidney, spleen or uterus tissue is very rare.9

Figure 1.2. The most common metastatic sites for breast cancer.
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1.4 Bone Metastatic Breast Cancer
Bone metastasis is one of the most studied organotropisms because bone metastasis
is extremely common in late stage breast, lung, and prostate cancers and because of the
way normal bones maintain homeostasis.9 Two cell types, bone-building osteoblasts and
bone-degrading osteoclasts, maintain bone homeostasis and their balance is destabilized
when cancers metastasize to the bone.9 Under non-cancerous conditions, osteoblasts and
osteoclasts actively remodel bone to preserve the strength of the skeletal system, but loss
of their homeostasis leads to diseases such as osteoporosis and osteopetrosis. Breast cancer
can tip the balance to generate either in favor of osteoblasts or osteoclasts, but most often
the bone metastases are osteolytic.9,10
Breast cancer cells are often not able to carry out bone alteration because these
metastatic cells are not specialized to do so. Yet, bone metastatic cells secrete factors to
promote the production of receptor activator of nuclear factor kappa-B ligand (RANKL),
an essential signaling molecule for osteoclast differentiation, and reduce the expression of
osteoprotegerin (OPG), a decoy receptor for RANKL.10,11 By altering the production of
RANKL and OPG, the bone metastatic breast cancer cells promote the activation of
osteoclasts which leads to bone degradation.

1.5 MDA-MB-231
The MDA-MB-231 is a bone metastatic breast cancer cell line that is triple negative
meaning that estrogen recptors (ER) and progesterone receptors (PR) are not present and
they do not overexpress human epidermal growth factor receptor-2 (HER-2).12,13 Bone
metastatic sub-populations of MDA-MB-231were genetically profiled and have been
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found to contain bone metastasis gene signatures like osteopontin (OPN), connective tissue
growth factor (CTGF), interleukin 11 (IL-11), CXC motif chemokine receptor 4 (CXCR4),
matrix metalloproteinase-1 (MMP1), and ADAM metallopeptidase with thrombospondin
type 1 (ADAMTS1).5,14 This cell line also has high expressions of Ras and Rho family
proteins.13 The Ras and Rho family proteins are small signaling G proteins which are
known as GTPases.13
This cell line is an epithelial breast cancer line from a 51-year-old Caucasian
female. The line was established from a pleural effusion of the woman who had a metastatic
mammary adenocarcinoma.13 MDA-MB-231 is a highly invasive and aggressive line of
triple-negative breast cancer that belongs to the claudin-low molecular subtype
classification.12 Morphologically, these cells are endothelial-like and have stellate
projections that can bridge cell colonies.15 The MDA-MB-231 cell line is commonly used
for drug discovery studies and is an established too for bone metastasis research.16

1.6 Cholesterol and the Mevalonate Pathway
Cholesterol is a vital part of membrane bilayers because it plays key roles in their
structure, stability, and function. Some specific functions of cholesterol are regulating the
activity of membrane-bound transporters, ion channels, and signaling molecules along with
being the precursor in steroid hormone and bile acid synthesis.17 Although cholesterol
comes from diet and ends up as many different products in different cells, the main pathway
used to make cholesterol for cellular functions is its de novo synthesis from acetyl-CoA.17
This pathway is known as the mevalonate pathway, illustrated in Figure 1, and produces
not only cholesterol but also dolichol, unbiquinol, and isoprenoids. The rate limiting step
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of the mevalonate pathway is the reduction of HMG-CoA to mevalonate which is catalyzed
by HMG-CoA reductase. To get HMG-CoA, two acetyl CoAs react with thiolase as the
catalase to produce acetoacetyl-CoA which is then catalyzed by HMG-CoA synthase to
make HMG-CoA.18 Mevalonate kinase then phosphorylates the mevalonate to
pyrophosphomevalonate which is then converted to isopentenyl pyrophosphate by the
enzyme mevalonate-5-pyrophosphate decarboxylase.17,18 Isopentenyl pyrophosphate can
reversibly convert to dimethylallylpyrophosphate which can in turn react with isopentenyl
pyrophosphate with the aid of the enzyme farnesyl diphosphate synthase to make the 10carbon isoprenoid geranyl pyrophosphate.17,18 Another unit of isopentenyl pyrophosphate
is added to generate farnesyl pyrophosphate which can then accept another isopentenyl
pyrophosphate to synthesize geranylgeranyl pyrophosphate, or the isoprenoid geranyl
pyrophosphate can be used to synthesize cholesterol, squalene, dolichol ubiquinone and
other products.2,17
Farnesyl pyrophosphate and geranylgeranyl pyrophosphates are used to prenylate proteins
in the Ras, Rho, and Ras homolog enriched in brain (Rheb), family which are
overexpressed in cancers and cause unregulated growth.18 These isoprenoids act as lipid
anchors for signaling proteins including the GTPases Ras and Rho families which have
been identified as oncogenes.17 In cancers, the mevalonate pathway is upregulated so more
cholesterol is also produced. Geranylgeranyl pyrophosphates are also used in the synthesis
of CoQ10, an important factor in mitochondrial respiration.19 Enhanced cholesterol
requirements are very closely associated with cell proliferation and tumor growth.20,21,22,
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Figure 1.3 Mevalonate pathway with statin drug target and isoprenylated proteins labeled.
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1.7 Statins
Statins are a class of drug commonly prescribed for cholesterol reduction. There
are currently seven FDA approved statin drugs which are given to patients to control
cholesterol levels and reduce the risk of stroke, heart attack, and death by heart disease.23
The serious adverse effects of statin treatment are rhabdomyolysis (0.44 cases per 10,000
patients) and liver failure (1 case per million patients) are very rare.14,23 Statins are a 3hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors which
reversibly inhibit the conversion of HMG-CoA to mevalonate. Inhibiting this conversion
inhibits cholesterol biosynthesis because mevalonate is the rate-limiting step of the
reaction.14 Although statins have a similar basic structure, they have variable moieties and
therefore different properties. The lipophilic statins are lovastatin, simvastatin, fluvastatin,
pitavastatin, and atorvastatin.7,14 The hydrophilic statins are pravastatin and
rosuvastatin.7,14 The solubility of the drug affects how the drugs enter liver cells; the
lipophilic statins enter the cells by diffusion and the hydrophilic statins enter the cells via
the organic anion transporter protein 2 (OATP2).7 Because the statins have different
chemical structures and different pharmacokinetics, it is plausible that specific statins will
differentially interact with the biochemical processes in different cancers.
In vivo studies done mostly on rodent models, show support for the potential role
of statins in tumor suppression. In one rodent model-based breast cancer study, rats on
simvastatin had a lower incidence rate of radiation-induced mammary tumors24 and another
study showed lovastatin reduced sarcomatoid mammary carcinoma formation and
metastasis in a mouse model.10 Lipophilic statins were also found to possess significant
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antitumor properties in mice by decreasing phosphorylated mitogen-activated protein
kinase-1 (p-MEK1) and mitogen activated protein kinase 2 (MEK2) levels that act in Ras
and Raf cascades that drive cell proliferation.11 Anti-cancer properties of statins in animal
models were also shown for ovarian tumors,18 mammary tumors,25 lung tumors,26 and
prostate tumors.27
Hydrophilic Statins
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Figure 1.4 Hydrophilic and lipophilic statin drug structure.
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1.8 Lovastatin
Lovastatin is a lipophilic 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase inhibitor. This drug reduces the synthesis of intracellular cholesterol and the
isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate by inhibiting the
conversion of HMG-CoA to mevalonate.18 The empirical formula of lovastatin is C24H36O5
and has a molecular weight of 404.547 g/mol.
Lovastatin is commonly prescribed to reduce cardiovascular disease incidences and
to treat hyper-cholesterolemia.18 Lovastatin can be found naturally in certain mushrooms
(e.g., oyster mushrooms) such as Pleurotus ostreatus,28 but the natural product was
originally isolated from Aspergillus terreus.29 In its native form, lovastatin is inactive and
is in what is known as its lactone form. The lactone ring in the inactive form is hydrolyzed
in vivo to the β-hydroxy acid form of lovastatin which is the active form.30 The β-hydroxy
acid site of the active form of lovastatin resembles the structure of HMG-CoA, therefore
can bind to HMG-CoA reductase and act as a reversible inhibitor to block the function of
the enzyme and reduce the amount of mevalonate.31
HO

HO

O

COOH
OH

O

O

O

H

O

H

O

Lovastatin
(Active; ß-hydroxy acid form)

Lovastatin
(Inactive; lactone form)

Figure 1.5. The inactive lactone form of lovastatin and the active the β-hydroxy acid form
of lovastatin.31
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Mevalonate

HMG-CoA
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COOH
OH

R

β-hydroxyacid form
of statins
Figure 1.6. Structural similarity between HMG-CoA and the active form of lovastatin, and
the mechanism of inhibition.31
Lovastatin also reduces the amount of CoQ10 produced because farnesyl
pyrophosphate from the mevalonate pathway is used for its synthesis.19 Lovastatin also
decreases the levels of CoQ10’s lipoprotein transport carriers.32 In animal studies, CoQ10
levels in both blood and tissues were depleted after lovastatin treatment.32 In some patients
on high-dose lovastatin therapy, mitochondrial function was also decreased in patients who
had low levels of CoQ10 in the muscle.33 This mitochondrial depletion of CoQ10 can cause
side effects in some patients such as muscle aches and weakness which may prevent some
patients from tolerating lovastatin and other statin therapy.33
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2 Methods
2.1 Introduction to cell viability testing
Cell viability testing is the most commonly used assay to determine the number of
viable cells in multi-well plates. This method is often used to screen compounds to
determine if those molecules can inhibit cell proliferation and show cytotoxic effects that
cause cell death. Some more elaborate cell viability methods can be used to monitor
metabolic activity, enzymatic activity, and protease activity. The method used in this
experiment, the sulforhodamine B method, is discussed in the methods section. This
experiment tests the effects of lovastatin (MevacorÒ) and CoQ10 at different
concentrations on different breast cancer cell lines, MDA-MB-231, BoM-1833 (BoM)
derived from MDA-MB--231, MCF7/BoM, and T47D.

2.2 Cell lines and cell culture
Human breast tumor T47D, and MDA-MB-231 cells were purchased from ATCC. The
MDA-MB-231-derived subclones BoM-1833 (BoM, bone metastatic) and MCF7/BoM
were generated by Dr. J. Massagué’s group at the Memorial Sloan Kettering Cancer
Center, New York City, New York. The cells were maintained in RPMI 1640 media with
L-glutamine (2 mM) (Corning), supplemented with fetal bovine serum [FBS, 10% (v/v),
Hyclone], penicillin (50 units/mL) and streptomycin (50 µg/mL) (Lonza) (referred to as
‘complete media’).
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2.3 Preparation of Lovastatin and CoQ10 solutions
Both CoQ10 and lovastatin were purchased from Sigma-Aldrich, dissolved in
specified solvents to obtain stock solutions (CoQ10: 1 mM in EtOH; and lovastatin: 4 mM
in DMSO), and stored at –20°C. In serum-free media, 100 µL of lovastatin solution was
prepared as a 2x working solution (final concentrations in a volume of 200 µL at 0.03 µM,
0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, and 30 µM, respectively). For CoQ10, the final
concentrations are 0.1 µM, 0.3 µM, 1 µM, 3 µM, and 10 µM.

2.4 Sulforhodamine B (SRB)-based cell viability assay
Cells were seeded at the density of 30,000 cells/well into 96-well plates in a volume
of 100 µL/well complete media and incubated at 37°C in a humidified environment that
contains 5% CO2:95% Air for 24 hours. After incubation, test compounds, CoQ10 and
lovastatin, diluted separately in serum-free RPMI 1640 media with L-glutamine (2 mM)
and penicillin/streptomycin were added in a volume of 100 µL/well. The compounds were
prepared as stock solutions in EtOH (for CoQ10) or DMSO (for lovastatin), and the final
solvent concentrations were £ 0.25% (v/v). The incubation continued for another 48 h and
the cells were fixed with trichloroacetic acid (TCA) by replacing 100 µL conditioned media
with an equal volume of 20% TCA in 1x PBS. After 1 h at 4°C, the plates were washed
four times with tap water and air dry. The fixed cells were stained with 0.4% SRB (w/v,
1% acetic acid) in a volume of 100 µL/well at room temperature for 10 min. The plates
were washed four times with 1% acetic acid and air dry. A Trizma® base solution (10 µM)
was added in a volume of 200 µL/well to solubilize SRB. The plates were read at 490 nm
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with background at 630 nm subtracted. Cell viability data are presented as ‘% Control’
calculated using the formula where OD is the optical density:
% Control = (ODcompound/ODcontrol) × 100
The % Control data can be used to calculate the ‘% Inhibition’ using the formula:
% Inhibition = [1 – (ODcompound/ODcontrol)] × 100
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3 Results and Discussion
3.1 Percent Inhibition curves
The percentage inhibition of lovastatin and CoQ10 at different concentrations in
different cell lines was graphed to show the inhibition as it related to concentration.
These graphs were generated using the software Prism 7 (GraphPad).

Lovastatin - BoM
100

% Inhibition

75
50
25
0
-25

C

10-7

10-6

10-5

10-4

Lovastatin (M)
Figure 3.1. Percentage inhibition of BoM cell line by different concentrations of
lovastatin. C is the control which is the cell line in media with no added lovastatin. Data
shown are average ± standard deviation (n=4). The IC50 value for lovastatin on this cell
line is 4.89×10-6 M.	
  

16
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10-5

10-4

Lovastatin (M)
Figure 3.2. Percentage inhibition of MCF7/BoM cell line by different concentrations of
lovastatin. C is the control which is the cell line in media with no added lovastatin. Data
shown are average ± standard deviation (n=4). The IC50 value for lovastatin on this cell
line is 4.06×10-6 M.
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Lovastatin (M)
Figure 3.3. Percentage inhibition of T47D cell line by different concentrations of
lovastatin. C is the control which is the cell line in media with no added lovastatin. Data
shown are average ± standard deviation (n=4). There is no IC50 value for lovastatin
treatment of this cell line.
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Figure 3.4. Percentage inhibition of BoM cell line by different concentrations of CoQ10.
C is the control which is the cell line in media with no added CoQ10. Data shown are
average ± standard deviation (n=4). The IC50 value for CoQ10 on this cell line is
5.46×10-7 M.
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Figure 3.5. Percentage inhibition of MCF7/BoM cell line by different concentrations of
CoQ10. C is the control which is the cell line in media with no added CoQ10. Data
shown are average ± standard deviation (n=4). The IC50 value for CoQ10 on this cell
line is 8.86×10-7 M.
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Figure 3.6. Percent inhibition of T47D cell line by different concentrations of CoQ10. C
is the control which is the cell line in media with no added CoQ10. Data shown are
average ± standard deviation (n=4). The IC50 value for CoQ10 on this cell line is
2.15×10-7 M.

The above graphs illustrate the inhibitory effects lovastatin and CoQ10 have on the
breast cancer cell lines BoM, MCF7/BoM, and T47D. The inhibition data for MDA-MB231 was not included because the high cell concentration produced too much stress for this
cell line. The cells were unhealthy after the first incubation and the media turned yellow,
so the data was excluded from this experiment.
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The lovastatin inhibition graphs for BoM and MCF7/BoM cell lines show
sigmoidal curves which both reach 98% inhibition at high concentrations (30 µM) of
lovastatin. For the T47D cell line, the lovastatin treatment barely inhibited the cell with the
highest concentration of lovastatin (30 µM) only inhibiting growth by 22%.
The CoQ10 inhibition graphs for BoM and MCF7/BoM also show sigmoidal curves
reaching about 98% inhibition at the maximum concentration of CoQ10 (10 µM). The
T47D cell line showed a sigmoidal curve when treated with CoQ10, but was only inhibited
by 91% at the highest concentration of CoQ10 (10 µM).
The half-maximal inhibitory concentration, IC50, was determined from the percent
inhibition graphs. The IC50 is the concentration of a particular drug that is needed to inhibit
a biological process, in this case cell growth, by half. The lower the value of the IC50 of a
drug means the drug is more potent. The IC50 values are listed in the chart below.
Cell line
BoM

IC50 Lovastatin
4.89×10-06 M

95%CI Lovastatin IC50 CoQ10
n/a*

5.46×10-07 M

95%CI CoQ10
4.56×10-07 6.35×10-07

MCF7/BoM

4.06×10-06 M

n/a*

8.86×10-07 M

8.517×10-07 9.56×10-07

T47D

n/a

n/a

2.15×10-07 M

n/a*

Table 3.1. IC50 values and 95% CI for lovastatin and CoQ10 on different breast cancer
cell lines. There is no IC50 value for lovastatin with the T47D cell line because the
compound did not completely inhibit the cell replication at high concentrations. *There is
no 95% CI for these IC50 values because the IC50 was determined from the best-fit curve.
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The IC50 values for lovastatin were similar for both the BoM and MCF7/BoM cell
lines, 4.89×10-6 M and 4.06×10-6 M respectively. There was no IC50 value for lovastatin
for the T47D cell line and at the highest concentrations of lovastatin, there was no more
than 22% inhibition. The IC50 values for CoQ10 were 5.46×10-7 M for BoM, 8.86×10-7 M
for MCF7/BoM, and 2.15×10-07 M for T47D. Treatment with CoQ10 inhibited T47D up to
91% at the concentration of 10 µM, so the IC50 value was estimated using the best fit
sigmoidal curve from Figure 3.6.
One difference between T47D and the other cell lines is that BoM and MCF7/BoM
are estrogen independent, bone metastatic cell lines, which T47D is estrogen dependent
and not bone metastatic. The mevalonate pathway could possibly play a bigger role in cell
replication and growth for the BoM and MCF7/BoM cell lines compared to the role it plays
in T47D. Because both lovastatin and CoQ10 inhibit BoM and MCF7/BoM, cholesterol
regulation seems important for these bone metastatic cell lines.
The inhibition caused by lovastatin could be due to a couple of different reasons.
First, inhibiting HMG-CoA reductase inhibits the farnesyl pyrophosphate synthesis which
is a precursor for the synthesis of many molecules including CoQ10. Decreasing the
amount of CoQ10 available will inhibit ATP synthesis through oxidative phosphorylation,
although this would probably not affect cancer cells as much considering their glycolytic
nature. To see if the inhibition caused by lovastatin is related to CoQ10 production from
the mevalonate pathway, a drug combination assay could be done. If adding CoQ10 to cells
treated with lovastatin reverses the inhibition effects, then the cell growth inhibition could
likely be caused by the lovastatin preventing production of CoQ10.
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Inhibiting HMG-CoA reductase inhibits the production of farnesyl pyrophosphate
and gernylgernyl pyrophosphate which are vital in the post-translational modification of
many GTPases specifically those in the Ras and Rho family which are upregulated in
cancers.34,35 These isoprenoids act as lipid attachments for intracellular signaling molecules
like Rho and Ras GTPases. Because Ras and Rho play significant roles in cancers by
promoting cell cycle progression, resisting apoptosis, neovascularization, and promoting
metastasis, preventing necessary post-translational modification for these proteins will
inhibit cancer cell growth.35 Perhaps the isoprenylation of GTPases is more vital for cell
survival in the BoM and MCF7/BoM cell lines than it is in the T47D cell line, but an assay
that specifically quantifies the isoprenylation of GTPases in the presence and absence of
lovastatin for the different cell lines would be needed to draw that conclusion.
The inhibition caused by CoQ10 is more elusive in explanation and its beneficial
effects on cancer is highly controversial. Several human studies have tested adding CoQ10
supplements with traditional chemotherapy which showed CoQ10 aiding in the prevention
of metastasis, improved quality of life, and in some patients, apparent partial remission.36
The mechanisms explaining these effects of CoQ10 are poorly understood. One study
found that CoQ10 inhibits the activity of matrix metalloproteinase 2 (MMP-2), an
important molecule in metastasis. The MMP-2’s activity is mediated by mitochondrial
ROS and CoQ10 is a mitochondrial ROS regulator, so CoQ10 inhibits MMP-2’s activity
most likely through ROS regulation.37 Addition of CoQ10 could possibly regulate other
reactions through altering ROS production, but many more specific assays would need to
be performed before drawing this conclusion. Another possible explanation could lie in
membrane dynamics. The compound CoQ10 is found contained between membrane
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bilayers, so very high concentration of extracellular CoQ10 could have caused the
inhibition in this specific experiment by altering membranes. Membrane surface analysis
using methods such as cryo-electron microscopy, laser scanning microscopy, or total
internal reflection fluorescence may help to address this issue.
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4 Conclusion
These experiments tested the effects of lovastatin and CoQ10 on the breast cancer
cell lines, MDA-MB-231, BoM-1833 (BoM) derived from MDA-231, MCF7/BoM, and
T47D. Percent inhibition curves based on concentration were generated, and IC50 values
were obtained. The MDA-MB-231 cell line was too stressed during the experiment, so the
percent inhibition data for it was discarded because it was not reliable. The IC50 values for
lovastatin were found to be 5.46×10-07 M for BoM and 4.06×10-06 M for MCF7/BoM, but
there was no IC50 value for the T47D trial because lovastatin did not sufficiently inhibit the
cell lines growth. The IC50 values for CoQ10 were 5.46×10-07 M for BoM, 8.86×10-07 M
for MCF7/BoM, and 2.15×10-07 M for T47D. These results suggest that lovastatin and
CoQ10 are both viable drugs to further investigate as potential anti-cancer drugs.

26

5 References
1.   Heiden, M. G. V., Cantley, L. C., and Thompson, C. B. (2009) Understanding the
Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science. 324,
1029–1033
2.   Ribas, V., García-Ruiz, C., and Fernández-Checa, J. C. (2016) Mitochondria,
cholesterol and cancer cell metabolism. Clinical and Translational Medicine. 5,
22
3.   Langley, R. R., and Fidler, I. J. (2011) The seed and soil hypothesis revisited-The
role of tumor-stroma interactions in metastasis to different organs. International
Journal of Cancer. 128, 2527–2535
4.   Chambers, A. F., Groom, A. C., and Macdonald, I. C. (2002) Metastasis:
Dissemination and growth of cancer cells in metastatic sites. Nature Reviews
Cancer. 2, 563–572
5.   Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’
hypothesis revisited. Nature Reviews Cancer. 3, 453
6.   Poste, G. & Fidler, I. J. (1980). The pathogenesis of cancer metastasis. Nature.
283, 139–146
7.   Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale,
A., Olshen, A. B., Gerald, W. L., and Massagué, J. (2005) Genes that mediate
breast cancer metastasis to lung. Nature. 436, 518–524
8.   Kang, Y. (2005) Functional genomic analysis of cancer metastasis: biologic
insights and clinical implications. Expert Review of Molecular Diagnostics. 5,
385–395
9.   Lu, X., and Kang, Y. (2007) Organotropism of Breast Cancer Metastasis. Journal
of Mammary Gland Biology and Neoplasia. 12, 153–162
10.  Mundy, G. R. (2002) Metastasis: Metastasis to bone: causes, consequences and
therapeutic opportunities. Nature Reviews Cancer. 2, 584–593
11.  Harada, S.-I., and Rodan, G. A. (2003) Control of osteoblast function and
regulation of bone mass. Nature. 423, 349–355
12.  Holliday, D. L., and Speirs, V. (2011) Choosing the right cell line for breast
cancer research. Breast Cancer Research. 13, 215
13.  Cailleau, R., Olivé, M., and Cruciger, Q. V. J. (1978) Long-term human breast
carcinoma cell lines of metastatic origin: Preliminary characterization. In
Vitro. 14, 911–915
14.  Kang, Y., Siegel, P., Shu, W., Drobnjak, M., Kakonen, S., Cordon-Cardo, C., et
al. (2003) A multigenic program mediating breast cancer metastasis to bone.
Cancer Cell. 3, 537-549
15.  Harrell, J. C., Pfefferle, A. D., Zalles, N., Prat, A., Fan, C., Khramtsov, A.,
Olopade, O. I., Troester, M. A., Dudley, A. C., and Perou, C. M. (2013)
Endothelial-like properties of claudin-low breast cancer cells promote tumor
vascular permeability and metastasis. Clinical & Experimental Metastasis. 31,
33–45

27

16.  Simmons, J. K., Hildreth, B. E., Supsavhad, W., Elshafae, S. M., Hassan, B. B.,
Dirksen, W. P., Toribio, R. E., and Rosol, T. J. (2015) Animal Models of Bone
Metastasis. Veterinary Pathology. 52, 827–841
17.  Brown, A. J. (2007) Cholesterol, Statins And Cancer. Clinical and Experimental
Pharmacology and Physiology. 34, 135–141
18.  Gronich, N., and Rennert, G. (2013) Beyond aspirin—cancer prevention with
statins, metformin and bisphosphonates. Nature Reviews Clinical Oncology. 10,
625–642
19.  Deichmann , R., Lavie, C., and Andrews, S. (2010) Coenzyme q10 and statininduced mitochondrial dysfunction. . The Ochsner Journal. 10, 16–21
20.  Dang, C. V. (2012) Links between metabolism and cancer. Genes &
Development. 26, 877–890
21.  Sasso, G. L., Celli, N., Caboni, M., Murzilli, S., Salvatore, L., Morgano, A.,
Vacca, M., Pagliani, T., Parini, P., and Moschetta, A. (2009) Down-regulation of
the LXR transcriptome provides the requisite cholesterol levels to proliferating
hepatocytes. Hepatology. 51, 1334–1344
22.  Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F.,
Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., and Penn, L.
Z. (2010) Dysregulation of the mevalonate pathway promotes
transformation. Proceedings of the National Academy of Sciences. 107, 15051–
15056
23.  Neuvonen, P. J., Backman, J. T., and Niemi, M. (2008) Pharmacokinetic
Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin,
Fluvastatin and Pravastatin. Clinical Pharmacokinetics. 47, 463–474
24.  Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., ManovaTodorova, K., Blasberg, R., Gerald, W. L., and Massague, J. (2005) Breast cancer
bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of
the National Academy of Sciences. 102, 13909–13914
25.  Alonso, D. F., Farina, H. G., Skilton, G., Gabri, M. R., Lorenzo, M. S. D., and
Gomez, D. E. (1998) Reduction of mouse mammary tumor formation and
metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol
synthesis. Breast Cancer Research and Treatment. 50, 83–93
26.  Cho, S.-J., Kim, J. S., Kim, J. M., Lee, J. Y., Jung, H. C., and Song, I. S. (2008)
Simvastatin induces apoptosis in human colon cancer cells and in tumor
xenografts, and attenuates colitis-associated colon cancer in mice. International
Journal of Cancer. 123, 951–957
27.  Roy, M., Kung, H., and Ghosh, P. (2011) Statins and prostate cancer: role of
cholesterol inhibition vs. prevention of small GTP-binding proteins. American
Journal of Cancer Research. 1, 542–561
28.  Alarcón, J., Águila, S., Arancibia-Avila, P., Fuentes, O., Zamorano-Ponce, E., and
Hernández, M. (2003) Production and Purification of Statins from Pleurotus
ostreatus (Basidiomycetes) Strains. Zeitschrift für Naturforschung C. 58, 62-64
29.  Endo, A. (2004) The origin of the statins. Atherosclerosis Supplements. 5, 125–
130
30.  Nigam, V. K. (2015) Screening Of Different Fungi For Production Of
Lovastatin. Asian Journal of Biomedical and Pharmaceutical Sciences. 5, 24–29

28

31.  Goswami, S., Vidyarthi, A. S., Bhunia, B., and Mandal, T. (2002) A review on
lovastatin and its production. Journal of Biochemical Technology.4, 581-587
32.  Littarru, G. P., and Langsjoen, P. (2007) Coenzyme Q10 and statins: Biochemical
and clinical implications. Mitochondrion. 7, S168-S174
33.  Paiva, H., Thelen, K., Coster, R., Smet, J., Paepe, B., Mattila, K., Laakso, J.,
Lehtimaki, T., Vonbergmann, K., and Lutjohann, D. (2005) High-dose statins and
skeletal muscle metabolism in humans: A randomized, controlled trial. Clinical
Pharmacology & Therapeutics. 78, 60–68
34.  Xiao, H., Qin, X., Ping, D., and Zuo, K. (2013) Inhibition of Rho and Rac
Geranylgeranylation by Atorvastatin Is Critical for Preservation of Endothelial
Junction Integrity. PLoS ONE. 10.1371/journal.pone.0059233
35.  Walker, K., and Olson, M. F. (2005) Targeting Ras and Rho GTPases as
opportunities for cancer therapeutics. Current Opinion in Genetics &
Development. 15, 62–68
36.  Lockwood, K., Moesgaard, S., Hanioka, T., and Folkers, K. (1994) Apparent
partial remission of breast cancer in ‘High Risk’ patients supplemented with
nutritional antioxidants, essential fatty acids and Coenzyme Q10. Molecular
Aspects of Medicine. 15, 231-240
37.  Bahar, M., Khaghani, S., Pasalar, P., Paknejad, M., Khorramizadeh, M. R.,
Mirmiranpour, H., and Nejad, S. G. (2010) Exogenous coenzyme Q10 modulates
MMP-2 activity in MCF-7 cell line as a breast cancer cellular model. Nutrition
Journal. 9, 62

29

